Grass pollen immunotherapy decreases the number of mast cells in the skin

Clinical and Experimental Allergy

Volumn 29, Issue 11, 1999, Pages 1490-1496

  Durham, S R ^a   Varney, V A ^a   Gaga, M ^a   Jacobson, M R ^a   Varga, E M ^a   Frew, A J ^b   Kay, A B ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Immunocytochemistry; Immunotherapy; Mast cells; Skin tests

Indexed keywords

ACRIVASTINE; CHYMASE; CROMOGLYCATE DISODIUM; PREDNISOLONE; TRYPTASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRASS POLLEN; HAY FEVER; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IMMUNOTHERAPY; MALE; MAST CELL; POLLEN; PRIORITY JOURNAL; SKIN; SKIN BIOPSY; SKIN TEST;

ADULT; ALLERGENS; BIOPSY; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAST CELLS; MIDDLE AGED; POACEAE; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SKIN;

EID: 0032707795     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.00678.x     Document Type: Article

References (37)

1. TC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 1989; 37:1509-15.
2. 2 Irani AM, Schwartz LB. Mast cell heterogeneity. Clin Exp Allergy 1989; 19:143-55.
3. 3 Benyon RC. The human skin mast cell. Clin Exp Allergy 1989; 19:375-87.
4. 4 Horsmanheimo L, Harvima IT, Jarvikallio A, Harvima RJ, Naukkarinen A, Horsmanheimo M. Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol 1994; 131:348-53.
5. 5 Ying S, Durham SR, Jacobson MR et al. T lymphocytes and mast cells express messenger RNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994; 82:200-6.
6. 6 Bradding P, Roberts JA, Britten KM et al. Interleukin-4, -5, and -6 and tumour necrosis factor α in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10:471-80.
7. + lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man. J Immunol 1988; 141:4158-64.
8. 8 Durham SR, Kay AB, Hamid Q. Changes in allergic inflammation associated with successful immunotherapy. Int Arch Allergy Immunol 1995; 107:282-4.
9. 9 Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991; 21:115-9.
10. 10 Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4 year follow-up study. Allergy 1995; 50:405-13.
11. 11 Bradley BL, Azzawi M, Jacobson MR et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88:661-74.
12. 12 Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late phase cutaneous responses. J Clin Invest 1993; 92:644-51.
13. 13 Irani AA, Schecter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 1986; 83:4464-8.
14. 14 Irani AM, Sampson HA, Schwartz LB. Mast cells in atopic dermatitis. Allergy 1989; 44:31-4.
15. 15 Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hayfever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52:472-82.
16. 16 Djurup R. The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy. Allergy 1985; 40:469-86.
17. 17 Creticos PS, Adkinson NF Jr, Kagey-Sobotka A et al. Nasal challenge with ragweed in hayfever patients: effects of immunotherapy. J Clin Invest 1985; 76:2247-53.
18. 18 Furin MJ, Norman PS, Creticos PS et al. Immunotherapy decreases antigen-induced eosinophil migration into the nasal cavity. J Allergy Clin Immunol 1991; 88:27-32.
19. 19 Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen allergic patients. J Allergy Clin Immunol 1988; 82:470-80.
20. 20 Rocklin RE, Sheffer AL, Greineder DL, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980; 302:1213-9.
21. 21 Fling JA, Ruff ME, Parker WA et al. Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989; 83:101-9.
22. + T cells from allergic individuals. J Exp Med 1993; 178:2130.
23. 23 Jutel M, Pichler WJ, Skrbie D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of 1FN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154:4187-94.
24. 24 O'Hehir RE, Aguilar BA, Schmidt TJ, Gollnick SO, Lamb JR. Functional inactivation of Dermatophagoides Spp. (house dust mite) reactive human T-cell clones. Clin Exp Allergy 1991; 21:209-15.
25. 25 O'Hehir RE, Yssel H, Verma S, de-Vries JE, Spits H, Lamb JR. Clonal analysis of differential lymphokine production in peptide and superantigen induced T-cell anergy. Int Immunol 1991; 3:819-26.
26. 26 Furitsu T, Saito H, Dvorak AM et al. Development of human mast cells in-vitro. Proc Natl Acad Sci USA 1989; 86:10039-43.
27. 27 Mitsui H, Furitsu T, Dvorak AM et al. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci USA 1993; 90:735-9.
28. 28 Irani A-M, Nilsson G, Miettinen U et al. Recombinant human stern cell factor simulates differentiation of mast cells from dispersed human fetal liver cells. Blood 1992; 80:3009-21.
29. 29 Valent P, Spanblochl E, Sperr WR et al. Induction of differentiation of human mast cells from hone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long term culture. Blood 1992; 80:2237-45.
30. 30 Rennick D, Hunte B, Holland G, Thompson-Snipes L. Cofactors are essential for stem cell factor-dependent growth and maturation of mast cell progenitors: comparative effects of interleukin-3 (IL-3), IL-4, IL-10 and fibroblasts. Blood 1995; 85:57-65.
31. 31 Nilsson G, Nilsson K. Effects of interleukin (IL) -13 on immediate-early response gene expression, phenotype and differentiation of human mast cells. Comparison with IL-4. Eur J Immunol 1995; 25:870-3.
32. 32 Valent P. The riddle of the mast cell: kit (CD117) -ligand as the missing link? Immunol Today 1994; 15:111-4.
33. 33 Matsuda H, Kannan Y, Ushio H et al. Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J Exp Med 1991 ; 174:7-14.
34. 34 Sillaber C, Sperr WR, Agis H, Spanblochl E, Lechner K, Valent P. Inhibition of stem cell factor dependent formation of human mast cells by interleukin-3 and interleukin-4. Int Arch Allergy Immunol 1994; 105:264-8.
35. 35 Church MK, Pao GJ, Holgate ST. Characterisation of histamine secretion from mechanically dispersed human lung mast cells: effects of anti-IgE, calcium ionophore A23187, compound 48/80, and basic polypeptides. J Immunol 1982; 129:2116-21.
36. 36 Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphokines in response to cross-linking of Fc epsilon RI or to calcium ionophores. Nature 1989; 339:64-7.
37. 37 Okayama Y, Quint D, Hunt TC. Expression of IL-4 mRNA in human dermal mast cells in response to FC epsilon receptor cross-linking in the presence of SCF (Abstract). J Allergy Clin Immunol 1993; 91:256.